IL6 and systemic lupus erythematosus: In systemic lupus erythematosus (SLE) model mice, Niclosamide significantly reduced IL-6, p-STAT3, and TCF-1 levels, down-regulated Tfh cells and IL-21 expression, and ameliorated mesangial matrix increase, moderate perivascular mononuclear cell infiltration, glomerular basement membrane thickening, and C3 immune complex deposition and other renal pathological features [15].